Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
ABVC Biopharma Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ABVC
Nasdaq
8731
https://abvcpharma.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for ABVC Biopharma Inc
ABVC BioPharma Shares Insights from Dr. Scott Irwin of Cedars-Sinai Medical Center over Depression in Cancer Patients Clinical Trials
- Dec 5th, 2023 1:30 pm
ABVC BioPharma Receives U.S. Patent for ADHD Treatment, a $32 Billion Market
- Nov 21st, 2023 1:30 pm
ABVC BioPharma Enters Definitive Agreement with Licensing Income Worth $467M and Royalties Up to $200M
- Nov 16th, 2023 3:05 pm
ABVC BioPharma Reports Third Quarter 2023 Financial and Operational Results
- Nov 15th, 2023 2:00 pm
ABVC BioPharma Entered Into a Term Sheet to License Global Rights of CNS Drugs with the Indications of MDD and ADHD to AiBtl BioPharma at the Valuation of $667 Million
- Oct 26th, 2023 12:30 pm
ABVC BioPharma Announces Completion of Subject Recruitment for Interim Analysis on ADHD Phase IIb Clinical Study
- Oct 17th, 2023 12:30 pm
ABVC BioPharma Receives Taiwanese Patent for Its Treatment of Major Depressive Disorder (MDD)
- Oct 9th, 2023 12:30 pm
ABVC BioPharma Provides Updates on ADHD Phase IIb Clinical Study
- Aug 23rd, 2023 12:30 pm
ABVC Executes Cooperation Agreement for Strategic Investments
- Aug 17th, 2023 1:19 pm
ABVC BioPharma Regains Compliance With Nasdaq's Minimum Bid Price Requirement
- Aug 10th, 2023 12:30 pm
ABVC Corporate Update and CEO's Letter to Shareholders
- Aug 7th, 2023 12:30 pm
ABVC Announces the Approval of the Plan for GMP Production Facilities of Vitargus by Taiwan Science Park Administration
- Aug 3rd, 2023 1:20 pm
ABVC Signs a Term Sheet to Earn Licensing Fees of up to $20M and Royalties of 5-12% of Net Sales
- Aug 1st, 2023 12:30 pm
ABVC BioPharma Announces Closing on $1.75 Million Registered Direct Offering
- Jul 31st, 2023 1:30 pm
ABVC BioPharma Announces Pricing of $1.75 Million Registered Direct Offering
- Jul 27th, 2023 1:22 pm
ABVC Signs Term Sheet to Acquire Real Estate Assets for Strategic Investments
- Jul 26th, 2023 12:30 pm
ABVC BioPharma Announces Reverse Stock Split
- Jul 24th, 2023 4:30 pm
The New CEO of ABVC BioPharma Takes Steps to Help Improve Cash Efficiency
- Jul 6th, 2023 12:30 pm
ABVC BioPharma, Inc. Announces New CEO as It Targets Further Growth
- Jun 26th, 2023 12:30 pm
ABVC BioPharma Subsidiary BioKey Projects $1.0 Million Proceeds From Dietary Supplement Production
- Jun 20th, 2023 12:30 pm
Scroll